Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Growth Shares
I would invest $5,000 in these growth shares
Share Gainers
Why I'm thinking of selling my REA Group Limited shares
Investing Strategies
Why timing the market doesn't work
⏸️ ASX Shares
Morgan Stanley names the best stocks for your portfolio and society
Healthcare Shares
Is it too late to buy shares in CSL Limited (ASX:CSL)?
Healthcare Shares
Should you buy these 3 ASX healthcare giants?
52-Week Highs
These shares just raced to 52-week highs: Is it too late to invest?
Share Gainers
Why these 4 ASX shares are ending the week on a high
Defensive Shares
At $90 billion: Is CSL Limited (ASX:CSL) overvalued?
Healthcare Shares
How to profit from Australia's ageing population on the ASX
Growth Shares
3 blue-chip healthcare companies to add to your portfolio
Growth Shares
3 top growth shares I would buy with $5,000
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
